EX-4.2



 Exhibit 4.2 

ATARA BIOTHERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

March 31, 2014 







 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
	 1.
	 	 Definitions
	  	 	1	  
			
	 2.    
	 	 Registration Rights
	  	 	3	  
		 	 2.1
	 	Request for Registration	  	 	3	  
		 	 2.2
	 	Company Registration	  	 	4	  
		 	 2.3
	 	Form S-3 Registration	  	 	5	  
		 	 2.4
	 	Obligations of the Company	  	 	7	  
		 	 2.5
	 	Information from Holder	  	 	9	  
		 	 2.6
	 	Expenses of Registration	  	 	9	  
		 	 2.7
	 	Delay of Registration	  	 	9	  
		 	 2.8
	 	Indemnification	  	 	9	  
		 	 2.9
	 	Reports Under the 1934 Act	  	 	12	  
		 	 2.10
	 	Assignment of Registration Rights	  	 	12	  
		 	 2.11
	 	Limitations on Subsequent Registration Rights	  	 	13	  
		 	 2.12
	 	“Market Stand-Off” Agreement	  	 	13	  
		 	 2.13
	 	Termination of Registration Rights	  	 	14	  
			
	 3.
	 	 Covenants of the Company
	  	 	14	  
		 	 3.1
	 	Delivery of Financial Information	  	 	14	  
		 	 3.2
	 	Termination of Information Covenants	  	 	15	  
		 	 3.3
	 	Right of First Offer	  	 	15	  
		 	 3.4
	 	Insurance	  	 	17	  
		 	 3.5
	 	Indemnification Matters	  	 	17	  
		 	 3.6
	 	Confidentiality	  	 	17	  
		 	 3.7
	 	Board Matters	  	 	18	  
		 	 3.8
	 	Qualified Small Business	  	 	18	  
		 	 3.9
	 	Investors’ Right of First Refusal	  	 	18	  
		 	 3.10
	 	Employee Vesting	  	 	20	  
			
	 4.
	 	 Miscellaneous
	  	 	20	  
		 	 4.1
	 	Successors and Assigns	  	 	20	  
		 	 4.2
	 	Governing Law	  	 	20	  
		 	 4.3
	 	Counterparts; Facsimile	  	 	20	  
		 	 4.4
	 	Titles and Subtitles	  	 	20	  
		 	 4.5
	 	Notices	  	 	21	  
		 	 4.6
	 	Expenses	  	 	21	  
		 	 4.7
	 	Entire Agreement; Amendments and Waivers	  	 	21	  
		 	 4.8
	 	Severability	  	 	21	  
		 	 4.9    
	 	Aggregation of Stock	  	 	22	  


					
			
	SCHEDULE A	 	Schedule of Investors	  	
	SCHEDULE B	 	Schedule of Common Holders	  	


  
 -i- 








 INVESTORS’ RIGHTS AGREEMENT 

This INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 31st day of March, 2014, by and among Atara
Biotherapeutics, Inc., a Delaware corporation (the “Company”), the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and collectively as the
“Investors”, and the holders of Common Stock (as defined below) listed on Schedule B hereto, each of which is herein referred to as a “Common Holder” and collectively as the “Common
Holders”. 
 RECITALS 

WHEREAS, the Company, the Common Holders and the Investors are party to that certain Share Exchange Agreement of even date herewith
(the “Share Exchange Agreement”) pursuant to which the Investors will exchange certain shares of capital stock held by such Investors in each of Nina Biotherapeutics, Inc., Pinta Biotherapeutics, Inc. and Santa Maria
Biotherapeutics, Inc. (collectively, the “Project Companies”) for shares of capital stock of the Company (the “Share Exchange”);  

WHEREAS, the Investors and Common Holders were party to certain Amended and Restated Investors’ Rights Agreements with each of the
Project Companies; and 
 WHEREAS, the obligations in the Share Exchange Agreement are conditioned upon the execution and
delivery of this Agreement;  
 NOW, THEREFORE, in consideration of the foregoing premises and certain other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Definitions.
For purposes of this Agreement: 
 (a) The term “Act” means the Securities Act of 1933, as amended. 

(b) The term “Affiliate” means, with respect to any Person, any other Person who or which, directly or indirectly, controls,
is controlled by, or is under common control with such specified Person, including, without limitation, any general partner, officer, director or manager of such Person and any venture capital fund now or hereafter existing that is controlled by one
or more general partners or managing members of, or is under common investment management with, such Person. 
 (c) The term
“Board” means the Company’s Board of Directors, as constituted from time to time. 
 (d) The term “Form S-3” means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 

  
 -1- 








 (e) The term “Free Writing Prospectus” means a free-writing prospectus, as
defined in Rule 405. 
 (f) The term “Holder” means any Person owning or having the right to acquire Registrable Securities
or any assignee thereof in accordance with Section 2.10 of this Agreement; provided, however, that the Common Holders shall not be deemed to be Holders for purposes of Sections 2.1, 2.3, 2.11 and 4.7. 

(g) The term “Initial Offering” means the Company’s first firm commitment underwritten public offering of its
Common Stock under the Act. 
 (h) The term “1934 Act” means the Securities Exchange Act of 1934, as amended. 

(i) The term “Person” shall mean any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 (j) The terms “register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or
document. 
 (k) The term “Registrable Securities” means (i) the Common Stock issuable or issued upon
conversion of the Preferred Stock, (ii) shares of Common Stock issued to the Common Holders; provided, however, that such shares of Common Stock shall not be deemed Registrable Securities for the purposes of Sections 2.1,
2.3, 2.11, 3.1, 3.3 and 4.7 and (iii) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in
exchange for, or in replacement of, the shares referenced in (i) and (ii) above, excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which such Person’s rights under Section 2 of this
Agreement are not assigned. In addition, the number of shares of Registrable Securities outstanding shall equal the aggregate of the number of shares of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to
then exercisable or convertible securities that are, Registrable Securities. 
 (l) The term “Restated Certificate”
shall mean the Company’s Restated Certificate of Incorporation, as amended and/or restated from time to time. 
 (m) The term
“Rule 144” shall mean Rule 144 under the Act. 
 (n) The term “Rule 144(b)(1)(i)” shall mean
subsection (b)(1)(i) of Rule 144 under the Act as it applies to Persons who have held shares for more than one (1) year. 

(o) The term “Rule 405” shall mean Rule 405 under the Act. 

(p) The term “SEC” shall mean the Securities and Exchange Commission. 

  
 -2- 








 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Request for Registration. 

(a) Subject to the conditions of this Section 2.1, if the Company shall receive at any time after the earlier of (i) five
(5) years after the date of this Agreement or (ii) six (6) months after the effective date of the Initial Offering, a written request from the Holders of at least thirty-five percent (35%) of the Registrable Securities then
outstanding (for purposes of this Section 2.1, the “Initiating Holders”) that the Company file a registration statement under the Act covering the registration of Registrable Securities with an anticipated aggregate offering
price of at least $30,000,000, then the Company shall, within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 2.1, use its commercially reasonable
efforts to effect, as soon as practicable, the registration under the Act of all Registrable Securities that the Holders request to be registered in a written request received by the Company within twenty (20) days of the mailing of the
Company’s notice pursuant to this Section 2.1(a). 
 (b) If the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.1, and the Company shall include such information in the written notice referred to in
Section 2.1(a). In such event the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable
Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company (which underwriter or underwriters shall be reasonably acceptable to those Initiating Holders holding a
majority of the Registrable Securities then held by all Initiating Holders). Notwithstanding any other provision of this Section 2.1, if the underwriter advises the Company that marketing factors require a limitation on the number of securities
underwritten (including Registrable Securities), then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be
allocated to the Holders of such Registrable Securities pro rata based on the number of Registrable Securities held by all such Holders (including the Initiating Holders). In no event shall any Registrable Securities be excluded from such
underwriting unless all other securities are first excluded. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 

(c) Notwithstanding the foregoing, the Company shall not be required to effect a registration pursuant to this Section 2.1: 

(i) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such
registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act; or 

  
 -3- 








 (ii) after the Company has effected two (2) registrations pursuant to this
Section 2.1, and such registrations have been declared or ordered effective; or 
 (iii) during the period starting with the date
sixty (60) days prior to the Company’s good faith estimate of the date of the filing of and ending on a date one hundred eighty (180) days following the effective date of a Company-initiated
registration subject to Section 2.2 below, provided that the Company is actively employing in good faith its commercially reasonable efforts to cause such registration statement to become effective; or 

(iv) if the Initiating Holders propose to dispose of Registrable Securities that may be registered on
Form S-3 pursuant to Section 2.3 hereof; or 
 (v) if the Company shall furnish to Holders
requesting a registration statement pursuant to this Section 2.1 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental
to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of
the Initiating Holders; provided that such right shall be exercised by the Company not more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for the
account of itself or any other stockholder during such ninety (90) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or
transaction under Rule 145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a
registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered). 

2.2 Company Registration. 

(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the
Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities (other than (i) a registration relating to a demand pursuant to Section 2.1 of
this Agreement or (ii) a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any
form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within twenty
(20) days after mailing of such notice by the Company in accordance with Section 4.5 of this Agreement, the Company shall, subject to the provisions of Section 2.2(c) of this Agreement, use its commercially reasonable efforts to
cause to be registered under the Act all of the Registrable Securities that each such Holder requests to be registered. 

  
 -4- 








 (b) Right to Terminate Registration. The Company shall have the right to terminate or
withdraw any registration initiated by it under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall
be borne by the Company in accordance with Section 2.6 hereof. 
 (c) Underwriting Requirements. In connection with any offering
involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under this Section 2.2 to include any of the Holders’ securities in such underwriting unless they accept the terms of the
underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other Persons entitled to select the underwriters) and enter into an underwriting agreement in customary form with such underwriters, and then only
in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in
such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only
that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. In the event that the underwriters determine that less than all of the
Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned pro rata among the selling Holders based on the number of Registrable
Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) any Registrable Securities be excluded from such offering
unless all other stockholders’ securities have been first excluded from the offering, (ii) the amount of securities of the selling Holders included in the offering be reduced below thirty percent (30%) of the total amount of
securities included in such offering, unless such offering is the Initial Offering, in which case the selling Holders may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included
in such offering or (iii) any securities held by a Common Holder be included in such offering if any Registrable Securities held by any Holder other than a Common Holder (and that such Holder has requested to be registered) are excluded from
such offering. For purposes of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital fund, partnership or corporation, the affiliated venture capital
funds, partners, members, retired partners and stockholders of such Holder, or the estates and family members of any such partners, members and retired partners and any trusts for the benefit of any of the foregoing Persons shall be deemed to be a
single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of Registrable Securities owned by all such related entities and individuals. 

2.3 Form S-3 Registration. In case the Company shall receive from the Holders of at least
twenty-five percent (25%) of the Registrable Securities (for purposes of this Section 2.3, the “S-3 Initiating Holders”) a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company shall: 

  
 -5- 








 (a) promptly give written notice of the proposed registration, and any related qualification or
compliance, to all other Holders; and 
 (b) use its commercially reasonable efforts to effect, as soon as practicable, such registration
and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders’ Registrable Securities as are specified in such request, together with all or
such portion of the Registrable Securities of any other Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however,
that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 2.3: 

(i) if Form S-3 is not available for such offering by the Holders; 

(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $5,000,000; 

(iii) if the Company shall furnish to all Holders requesting a registration statement pursuant to this Section 2.3 a certificate signed
by the Company’s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such registration statement to be effected at such
time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the S-3 Initiating Holders; provided that such right shall be exercised by the
Company not more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for the account of itself or any other stockholder during such ninety (90) day period
(other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any form that does
not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered); 
 (iv) if the Company has, within the twelve (12) month
period preceding the date of such request, already effected two (2) registrations on Form S-3 pursuant to this Section 2.3; 

(v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service
of process in effecting such registration, qualification or compliance; 
 (vi) if the Company, within thirty (30) days of receipt of
the request of such S-3 Initiating Holders, gives notice of its bona fide intention to effect the filing of a registration statement with the SEC within one hundred twenty (120) days of receipt of such


  
 -6- 








 
request (other than a registration effected solely to qualify an employee benefit plan or to effect a business combination pursuant to Rule 145), provided that the Company is actively
employing in good faith its commercially reasonable efforts to cause such registration statement to become effective; or 
 (vii) during the
period starting with the date thirty (30) days prior to the Company’s good faith estimate of the date of the filing of and ending on a date ninety (90) days following the effective date of a
Company-initiated registration subject to Section 2.2 of this Agreement, provided that the Company is actively employing in good faith its commercially reasonable efforts to cause such registration
statement to become effective. 
 (c) If the S-3 Initiating Holders intend to distribute the Registrable Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.3 and the Company shall include such information in the written notice referred to in Section 2.3(a). The provisions
of Section 2.1(b) of this Agreement shall be applicable to such request (with the substitution of Section 2.3 for references to Section 2.1). 

(d) Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so
requested to be registered as soon as practicable after receipt of the request or requests of the S-3 Initiating Holders. Registrations effected pursuant to this Section 2.3 shall not be counted as requests for registration effected pursuant to
Section 2.1 of this Agreement. 
 2.4 Obligations of the Company. Whenever required under this Section 2 to effect the
registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the SEC
a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the Registration Statement has been completed; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement; 

(c) furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus and any Free Writing Prospectus, in
conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions; 

  
 -7- 








 (e) in the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering; 
 (f) notify each Holder of
Registrable Securities covered by such registration statement at any time when a prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) relating thereto is required to be delivered under the Act of the
happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing, and, at the request of any such Holder, the Company will, as soon as reasonably practicable, file and furnish to all such Holders a supplement or amendment
to such prospectus or Free Writing Prospectus (to the extent prepared by or on behalf of the Company) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a
material fact or omit to state any fact necessary to make the statements therein not misleading in light of the circumstances under which they were made; 

(g) cause all such Registrable Securities registered pursuant to this Section 2 to be listed on a national exchange or trading system and
on each securities exchange and trading system on which similar securities issued by the Company are then listed; and 
 (h) provide a
transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

Notwithstanding the provisions of this Section 2, the Company shall be entitled to postpone or suspend, for a reasonable period of time,
the filing, effectiveness or use of, or trading under, any registration statement if the Company shall determine that any such filing or the sale of any securities pursuant to such registration statement would in the good faith judgment of the
Board: 
 (i) materially impede, delay or interfere with any material pending or proposed financing, acquisition, corporate reorganization
or other similar transaction involving the Company for which the Board has authorized negotiations; 
 (ii) materially and adversely impair
the consummation of any pending or proposed material offering or sale of any class of securities by the Company; or 
 (iii) require
disclosure of material nonpublic information that, if disclosed at such time, would be materially harmful to the interests of the Company and its stockholders; provided, however, that during any such period all executive officers and
directors of the Company are also prohibited from selling securities of the Company (or any security of any of the Company’s subsidiaries or affiliates). 

  
 -8- 








 In the event of the suspension of effectiveness of any registration statement pursuant to this
Section 2.4, the applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of days the effectiveness of such registration statement was suspended. 

2.5 Information from Holder. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such
securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6 Expenses of
Registration. All expenses other than underwriting discounts and commissions incurred in connection with registrations, filings or qualifications pursuant to Sections 2.1, 2.2 and 2.3 of this Agreement, including, without limitation, all
registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders (not to exceed $50,000) shall be
borne by the Company. Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 or Section 2.3 of this Agreement if the registration request is
subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to
be included in the withdrawn registration) unless, in the case of a registration requested under Section 2.1 of this Agreement, the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration
pursuant to Section 2.1 of this Agreement; provided, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to
the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall
retain their rights pursuant to Sections 2.1 and 2.3 of this Agreement. 
 2.7 Delay of Registration. No Holder shall have any
right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. In the event any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, members, officers,
directors and stockholders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Act) for such Holder and each Person, if any, who controls such Holder or underwriter within the meaning of the Act or the
1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state
securities laws, insofar as such losses, claims, damages, or liabilities (or actions or proceedings, whether 

  
 -9- 








 
commenced or threatened, in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a “Violation”):
(i) any untrue or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus, final prospectus, or Free Writing Prospectus contained therein or any amendments or supplements
thereto, any issuer information (as defined in Rule 433 of the Act) filed or required to be filed pursuant to Rule 433(d) under the Act or any other document incident to such registration prepared by or on behalf of the Company or used or
referred to by the Company, (ii) the omission or alleged omission of a material fact required to be stated in such registration statement, or necessary to make the statements therein not misleading or (iii) any violation or alleged
violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, and the Company will reimburse each such Holder, underwriter, controlling
Person or other aforementioned Person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred;
provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or proceeding if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, action or proceeding to the extent that it arises out of or is based
upon a Violation that occurs in reliance upon, and in conformity with, written information furnished expressly for use in connection with such registration by any such Holder, underwriter, controlling Person or other aforementioned Person.

 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company,
each of its directors, each of its officers who has signed the registration statement, each Person, if any, who controls the Company within the meaning of the Act, legal counsel and accountants for the Company, any underwriter, any other Holder
selling securities in such registration statement and any controlling Person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing Persons may become subject,
under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, insofar as such losses, claims, damages or liabilities (or actions or proceedings, whether
commenced or threatened, in respect thereof) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such
Holder expressly for use in connection with such registration; and each such Holder will reimburse any Person intended to be indemnified pursuant to this Section 2.8(b) for any legal or other expenses reasonably incurred by such Person in
connection with investigating or defending any such loss, claim, damage, liability, action or proceeding as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or proceeding if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld), and provided that in
no event shall any indemnity under this Section 2.8(b) exceed the net proceeds from the offering received by such Holder. 

  
 -10- 








 (c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the
commencement of any action or proceeding (including any governmental action or proceeding) for which a party may be entitled to indemnification, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 2.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party so desires, jointly with any
other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be
represented without conflict by one counsel) shall have the right to retain one (1) separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying
party within a reasonable time of the commencement of any such action or proceeding, if prejudicial to its ability to defend such action or proceeding, shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.8 to the extent of such prejudice, but the omission to so deliver written notice to the indemnifying party will not relieve such indemnifying party of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) If the indemnification provided for in this Section 2.8 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand
in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; provided, however, that (i) no contribution by any Holder,
when combined with any amounts paid by such Holder pursuant to Section 2.8(b), shall exceed the net proceeds from the offering received by such Holder and (ii) no Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The relative fault of the indemnifying party and the indemnified party shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 (e)
Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing
provisions, the provisions in the underwriting agreement shall control; provided, however, that the underwriting agreement shall not, without a particular Holder’s written approval, (i) expand the indemnity obligation of such Holder beyond
the net proceeds from the offering received by such Holder as contemplated by Section 2.8(b) or (ii) expand the contribution to be made by such Holder, when combined with any amounts paid by such Holder pursuant to the indemnification
provisions contained in the underwriting agreement, beyond the net proceeds from the offering received by such Holder, as contemplated by Section 2.8(d). 

  
 -11- 








 (f) The obligations of the Company and Holders under this Section 2.8 shall survive the
completion of any offering of Registrable Securities in a registration statement under this Section 2 and otherwise. 
 2.9 Reports
Under the 1934 Act. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to: 
 (a) make and keep
public information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the Initial Offering; 

(b) file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it
has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested to avail any Holder of any rule or regulation of the SEC that
permits the selling of any such securities without registration or pursuant to such form. 
 2.10 Assignment of Registration Rights.
The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities that (a) is an Affiliate,
subsidiary, parent, partner, limited partner, retired partner, member or stockholder of a Holder, (b) is a Holder’s family member or trust for the benefit of an individual Holder or any of such Holder’s family members, or
(c) after such assignment or transfer, holds at least two million (2,000,000) shares of Registrable Securities (appropriately adjusted for any stock split, dividend, combination or other recapitalization), provided: (i) the
Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (ii) such
transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the provisions of Section 2.12 of this Agreement; and (iii) such assignment shall be
effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act. 

  
 -12- 








 2.11 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders holding a majority of the Registrable Securities then held by all Holders, enter into any agreement with any holder or prospective holder of any securities of the
Company that would allow such holder or prospective holder (a) to include any of such securities in any registration filed under Section 2.1, Section 2.2 or Section 2.3 of this Agreement, unless under the terms of such agreement,
such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the amount of the Registrable Securities of the Holders that are included or (b) to
demand registration of their securities. 
 2.12 “Market Stand-Off” Agreement. 

(a) Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on
the date of the final prospectus relating to the Initial Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days) (i) lend, offer, pledge, sell,
contract to sell (including, without limitation, any short sale), sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or
indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether such shares or any such securities are then owned by the Holder or are thereafter acquired), or (ii) enter into
any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by
delivery of Common Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 2.12 shall apply only to the Initial Offering, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting
agreement, and shall only be applicable to the Holders if all officers, directors and greater than one percent (1%) stockholders of the Company (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) enter into
similar agreements. The underwriters in connection with the Initial Offering are intended third-party beneficiaries of this Section 2.12 and shall have the right, power and authority to enforce the
provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the Initial Offering that are consistent with this Section 2.12 or that are
necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Holders subject to such agreements pro rata based on the
number of shares subject to such agreements. 
 In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other Person subject to the foregoing restriction) until the end of such period. 

(b) Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing all shares or
securities of the Company of each Holder (and the shares or securities of every other Person subject to the restriction contained in this Section 2.12): 

  
 -13- 








 THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD AFTER THE
EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL
OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 
 2.13 Termination of Registration Rights. No Holder shall be
entitled to exercise any right provided for in this Section 2: (a) after five (5) years following the consummation of the Initial Offering, (b) as to any Holder, such earlier time after the Initial Offering at which such
Holder (i) can sell all shares held by it in compliance with Rule 144(b)(1)(i), or (ii) holds one percent (1%) or less of the Company’s outstanding Common Stock and all Registrable Securities held by such Holder (together
with any Affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) can be sold in any three (3) month period without registration in compliance with Rule 144 or (c) after the consummation of a
Liquidation Event, as that term is defined in the Restated Certificate. 
 3. Covenants of the Company. 

3.1 Delivery of Financial Information. 

(a) Delivery of Financial Statements. The Company shall deliver to each Investor (or transferee of an Investor) that holds at least six
hundred sixty-six thousand six hundred sixty-six (666,666) shares of Registrable Securities (appropriately adjusted for any stock split, dividend, combination or other recapitalization) and Amgen Inc. (“Amgen”) for so long as
Amgen holds at least eighty percent (80%) of the shares of the Series A-1 Preferred Stock issued to it in connection with the Share Exchange (in each case, a “Major Investor”): 

(i) as soon as practicable, but in any event within one hundred and eighty (180) days after the end of each fiscal year of the Company,
an income statement for such fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail,
prepared in accordance with generally accepted accounting principles (“GAAP”), and, beginning with the financial statements for the fiscal year ended December 31, 2013 and all successive fiscal years, audited and certified by
independent public accountants of nationally recognized standing selected by the Company; 
 (ii) as soon as practicable, but in any event
within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, an unaudited income statement and statement of cash flows for such fiscal quarter and an unaudited balance sheet as of
the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (A) be subject to normal year-end audit adjustments and (B) not contain all notes thereto that may be required in accordance
with GAAP); and 

  
 -14- 








 (iii) as soon as practicable, but in any event within thirty (30) days after the end of
each of the first eleven calendar months of each fiscal year of the Company, a monthly cash report detailing the major categories of sources and uses of cash, comparing the book balances to the bank balances. 

(b) Delivery of Annual Budget. As soon as practicable, but in any event no later than the later of thirty (30) days prior to the
beginning of each fiscal year or such later date as shall be approved by the Board, an operating budget, approved by the Board, forecasting the Company’s revenues, expenses and cash position on a month to month basis for such upcoming fiscal
year. 
 3.2 Termination of Information Covenants. The covenants set forth in Section 3.1 shall terminate and be of no further
force or effect upon the earlier to occur of (a) the consummation of the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities
to the general public, (b) when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first occur and (c) the consummation of a Liquidation
Event, as that term is defined in the Restated Certificate. 
 3.3 Right of First Offer. Subject to the terms and conditions specified
in this Section 3.3, the Company hereby grants to each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For purposes of this Section 3.3, the term “Major
Investor” includes any general partners and Affiliates of a Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted it among itself and its partners and Affiliates in such proportions as it
deems appropriate. 
 Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable
for any shares of, its capital stock (including, without limitation, any such shares or securities issued in connection with debt securities) (“Shares”), the Company shall first make an offering of such Shares to each Major Investor
in accordance with the following provisions: 
 (a) The Company shall deliver a notice in accordance with Section 4.5
(“Notice”) to the Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered and (iii) the price and terms upon which it proposes to offer such Shares.

 (b) By written notification received by the Company within twenty (20) calendar days after the giving of Notice, each
Major Investor may elect to purchase, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of Registrable Securities issued and held by such Major Investor
(assuming full conversion and exercise of all convertible and exercisable securities then outstanding) bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all convertible and
exercisable securities then outstanding). At the expiration of such twenty (20) calendar day period, the Company shall promptly, in writing, notify each Major Investor that elects to purchase all the shares available to it (a
“Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise. During  

  
 -15- 








 
the ten (10) calendar day period commencing after the Company has given such notice to the Fully-Exercising Investors, each Fully-Exercising Investor
may elect to purchase that portion of the Shares for which Major Investors were entitled to subscribe, but which were not subscribed for by the Major Investors, that is equal to the proportion that the number of shares of Registrable Securities
issued and held by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares. 
 (c) If all Shares that
Major Investors are entitled to obtain pursuant to Section 3.3(b) of this Agreement are not elected to be obtained as provided in Section 3.3(b) of this Agreement, the Company may, during the ninety (90) day period following
the expiration of the period provided in Section 3.3(b) of this Agreement, offer the remaining unsubscribed portion of such Shares to any Person or Persons at a price not less than that, and upon terms no more favorable to the offeree than
those, specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder
shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 

(d) The right of first offer in this Section 3.3 shall not be applicable to (i) the issuance or sale of shares of Common Stock (or
options therefor) to employees, directors, consultants and other service providers for the primary purpose of soliciting or retaining their services pursuant to plans or agreements approved by the Board; (ii) the issuance of securities pursuant
to an underwritten public offering of shares of Common Stock registered under the Act, (iii) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities, (iv) the issuance of securities in
connection with a bona fide business acquisition by the Company, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, (v) the issuance of shares of capital stock pursuant to the Share Exchange Agreement,
(vi) the issuance of stock, warrants or other securities or rights pursuant to any equipment leasing arrangement or debt financing arrangement, which arrangement is approved by the Board and is primarily for non-equity financing purposes,
(vii) the issuance of stock, warrants or other securities or rights to Persons or entities with which the Company has business relationships, provided such issuances are approved by the Board and are primarily for non-equity financing
purposes or (viii) the issuance of securities that are unanimously approved by the Board as not being offered to any existing stockholder of the Company and not subject to this Section 3.3. In addition to the foregoing, the right of first
offer in this Section 3.3 shall not be applicable with respect to any Major Investor in any subsequent offering of Shares if (i) at the time of such offering, the Major Investor is not an “accredited investor,” as that term is
then defined in Rule 501(a) of the Act and (ii) such offering of Shares is otherwise being offered only to accredited investors. 

(e) The rights provided in this Section 3.3 may not be assigned or transferred by any Major Investor; provided, however,
that a Major Investor that is a venture capital fund may assign or transfer such rights to its Affiliates. 

  
 -16- 








 (f) The covenants set forth in this Section 3.3 shall terminate and be of no further force
or effect upon the consummation of (i) the Company’s sale of its Common Stock or other securities pursuant to Registration Statement under the Act (other than a registration statement relating either to the sale of securities to employees
of the Company pursuant to its stock option, stock purchase or similar plan or a SEC Rule 145 transaction) or (ii) a Liquidation Event, as that term is defined in the Restated Certificate. 

3.4 Insurance. 
 (a)
Key-Man Insurance. If requested by the Board, the Company shall obtain and maintain in full force and effect term life insurance in the amount of $1,000,000 on the life of Isaac Ciechanover, with proceeds payable to the Company until such
time as the Board determines that such insurance should be discontinued. 
 (b) Directors’ and Officers’ Insurance. The
Company shall use its commercially reasonable efforts to obtain from financially sound and reputable insurers directors and officers liability insurance in an amount and on terms and conditions satisfactory to the Board, and will use its
commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board determines that such insurance should be discontinued. 

3.5 Indemnification Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve
on the Board by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the
“Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to
provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full
amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Restated Certificate or Bylaws of the Company (or any agreement
between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims
against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to
any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the
rights of recovery of such Fund Director against the Company. 
 3.6 Confidentiality. Each Investor agrees, severally
and not jointly, to use the same degree of care as such Investor uses to protect its own confidential information for any information obtained pursuant to this Agreement or otherwise as a stockholder of the Company which the Company identifies in
writing as being proprietary or confidential and such Investor acknowledges that it will not, unless otherwise required by law or the rules of any national 

  
 -17- 








 
securities exchange, association or marketplace, disclose such information without the prior written consent of the Company except such information that (a) was in the public domain
prior to the time it was furnished to such Investor, (b) is or becomes (through no willful improper action or inaction by such Investor) generally available to the public, (c) was in its possession or known by such Investor without
restriction prior to receipt from the Company, (d) was rightfully disclosed to such Investor by a third party without restriction or (e) was independently developed without any use of the Company’s confidential information.
Notwithstanding the foregoing, each Investor that is a limited partnership or limited liability company may disclose such proprietary or confidential information to any former partners or members who retained an economic interest in such Investor,
current or prospective partner of the partnership or any subsequent partnership under common investment management, limited partner, general partner, member or management company of such Investor (or any employee or representative of any of the
foregoing) (each of the foregoing Persons, a “Permitted Disclosee”) or legal counsel, accountants or representatives for such Investor. Furthermore, nothing contained herein shall prevent any Investor or any Permitted Disclosee from
(i) entering into any business, entering into any agreement with a third party, or investing in or engaging in investment discussions with any other company (whether or not competitive with the Company), provided that such Investor or
Permitted Disclosee does not, except as permitted in accordance with this Section 3.6, disclose or otherwise make use of any proprietary or confidential information of the Company in connection with such activities, or (ii) making any
disclosures required by law, rule, regulation or court or other governmental order. 
 3.7 Board Matters. 

(a) Unless otherwise determined by the vote of a majority of the directors then in office, the Board shall meet at least quarterly in
accordance with an agreed-upon schedule. 
 (b) The Company hereby covenants and agrees that it shall not, without approval of the Board,
enter into or be a party to any transaction with any stockholder of the Company or any Affiliate of any stockholder of the Company, except for: (i) transactions contemplated by this Agreement, the Share Exchange Agreement, the other Ancillary
Agreements (as defined in the Share Exchange Agreement) or that are disclosed in the Schedule of Exceptions (as defined in the Share Exchange Agreement); or (ii) transactions that are not individually material and that are made in the
ordinary course of business. 
 3.8 Qualified Small Business. For so long as any of the shares of Preferred Stock are held by an
Investor (or a transferee in whose hands such shares are eligible to qualify as “Qualified Small Business Stock” as defined in Section 1202(c) of the Internal Revenue Code of 1986, as amended (the “Code”)), the
Company will use its reasonable best efforts to comply with the reporting and recordkeeping requirements of Section 1202 of the Code, any regulations promulgated thereunder and any similar state laws and regulations, unless the Board determines
that such qualification is inconsistent with the best interests of the Company and its stockholders. 
 3.9 Investors’ Right of First
Refusal. Subject to the terms and conditions specified in this Section 3.9, each Investor hereby grants to each other Investor a right of first refusal with respect to future sales by such Investor of all or a portion of the shares of the


  
 -18- 








 
Company’s Preferred Stock (or Common Stock issued upon conversion thereof) (“Preferred Shares”) held by such Investor. For purposes of this Section 3.9, the term
“Investor” includes any general partners and Affiliates of an Investor. An Investor shall be entitled to apportion the right of first refusal hereby granted it among itself and its partners and Affiliates in such proportions as it
deems appropriate. 
 Each time an Investor proposes to sell all or a portion of its Preferred Shares, the Investor shall offer to sell such
Preferred Shares to each other Investor in accordance with the following provisions: 
 (a) The Investor proposing to sell all or a portion
of its Preferred Shares (“Selling Investor”) shall deliver a notice in accordance with Section 4.5 (“Sale Notice”) to the other Investors stating (i) its bona fide intention to offer sell such Preferred
Shares, (ii) the number of such Preferred Shares to be sold and (iii) the price and terms upon which it proposes to sell such Preferred Shares. 

(b) By written notification received by the Selling Investor within twenty (20) calendar days after the giving of the Sale Notice, each
other Investor may elect to purchase, at the price and on the terms specified in the Sale Notice, up to that portion of such Preferred Shares to be sold by the Selling Investor that equals the proportion that the number of Preferred Shares held by
such Investor bears to the total number of Preferred Shares then held by all Investors other than the Selling Investor. At the expiration of such twenty (20) calendar day period, the Selling Investor shall promptly, in writing, notify each
other Investor that elects to purchase all the shares available to it (a “Purchasing Investor”) of any other Investor’s failure to do likewise. During the ten (10) calendar day period commencing after the Selling Investor
has given such notice to the Purchasing Investors, each Purchasing Investor may elect to purchase that portion of the Preferred Shares for which Investors were entitled to purchase, but which were not purchased by the Investors, that is equal to the
proportion that the number of Preferred Shares held by such Purchasing Investor bears to the total number of Preferred Shares held by all Purchasing Investors who wish to purchase some of the unsubscribed shares. 

(c) If all Preferred Shares that Investors are entitled to purchase pursuant to Section 3.9(b) of this Agreement are not elected to
be obtained as provided in Section 3.9(b) of this Agreement, the Selling Investor may, during the ninety (90) day period following the expiration of the ten (10) day period provided in Section 3.9(b) of this Agreement,
sell the remaining unpurchased portion of such Preferred Shares to any Person or Persons at a price not less than, and upon terms no more favorable to the purchaser than those specified in the Sale Notice. If the Selling Investor does not enter into
an agreement for the sale of the Preferred Shares within such ninety (90) day period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder shall be deemed to be revived and
such Preferred Shares shall not be sold unless first reoffered to the other Investors in accordance herewith. 
 (d) The right of first
refusal in this Section 3.9 shall not be applicable to any transfer without consideration, (i) to an Affiliate, partner, member, limited partner, retired partner, retired member or stockholder of an Investor or (ii) to the
Investor’s ancestors, descendants or spouse or to trusts for the benefit of such persons or the Investor; provided that in the event of any transfer made pursuant to the foregoing exemptions, (A) the transferring


  
 -19- 








 
Investor shall inform the other Investors of such transfer or gift prior to effecting it and (B) the transferee shall enter into a written agreement to be bound by and comply with all
provisions of this Agreement, as if it were an original Investor hereunder. Such transferred Preferred Shares shall remain “Preferred Shares” hereunder, and such pledgee, transferee or donee shall be treated as the “Investor” for
purposes of this Agreement. 
 (e) The agreements set forth in this Section 3.9 shall terminate and be of no further force or effect
upon the consummation of (i) the Company’s sale of its Common Stock or other securities pursuant to a Registration Statement under the Act (other than a registration statement relating either to the sale of securities to employees of the
Company pursuant to its stock option, stock purchase or similar plan or a SEC Rule 145 transaction) or (ii) a Liquidation Event, as that term is defined in the Restated Certificate. 

3.10 Employee Vesting. All employees and consultants of the Company or its subsidiaries who receive options to purchase shares of the
Company’s capital stock or receive restricted stock units after the date hereof shall be required to execute option or restricted stock agreements, as applicable. Unless otherwise approved by the Board, these agreements shall provide for
vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service (or the date of grant in the case of a grant to an existing
employee or consultant) and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months. 
 4.
Miscellaneous. 
 4.1 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other
than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

4.2 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements
among California residents entered into and to be performed entirely within California. 
 4.3 Counterparts; Facsimile. This Agreement
may be executed by electronic signature and in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. Counterparts may be delivered by facsimile,
electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

4.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 

  
 -20- 








 4.5 Notices. All notices and other communications given or made pursuant hereto shall be
in writing and shall be deemed effectively given upon the earlier to occur of actual receipt or: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business
hours of the recipient; if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices and other communications shall be sent to the respective parties at the addresses set forth on the signature pages attached
hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 4.5). 
 4.6 Expenses.
If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which
such party may be entitled. 
 4.7 Entire Agreement; Amendments and Waivers. This Agreement (including the Exhibits hereto, if
any) constitutes the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. Any term of this Agreement (other than Section 3.1, Section 3.2 and Section 3.3) may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Investors holding a majority of the Registrable
Securities; provided, however, that in the event that (i) any amendment or waiver adversely affects any Holder in a manner that is materially different from other Holders, such amendment or waiver shall also require the written
consent of such Holder, (ii) any amendment or waiver adversely affects the Series B Preferred Stock in a manner that is materially different from the other series of Preferred Stock, then such amendment or waiver shall also require the written
consent of Investors holding a majority of the then outstanding shares of Series B Preferred Stock, (iii) any amendment or waiver adversely affects the Series A-1 Preferred Stock in a manner that is materially different from the other series of
Preferred Stock, then such amendment or waiver shall also require the written consent of Amgen or (iv) such amendment or waiver adversely affects the obligations or rights of the Common Holders in a different manner than the other Holders, then
such amendment or waiver shall also require the written consent of the Common Holders holding a majority of the shares of Common Stock then held by all Common Holders. The provisions of Section 3.1, Section 3.2 and Section 3.3 may be
amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities then held by all of the
Major Investors. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities, each future holder of all such Registrable Securities and the Company. 

4.8 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of such provision or the remaining provisions of this Agreement. 

  
 -21- 








 4.9 Aggregation of Stock. All shares of Registrable Securities held or acquired by
affiliated entities (including affiliated venture capital funds or venture capital funds under common investment management) or Persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

 [Remainder of page intentionally left blank] 

  
 -22- 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

			
		 	COMPANY:
		
		 	ATARA BIOTHERAPEUTICS, INC.
		
		 	 /s/ Isaac Ciechanover

		 	Isaac Ciechanover, Chief Executive Officer
		
	Address:	 	3260 Bayshore Blvd
		 	Brisbane, CA 94005

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTOR:
		
		 	CELGENE CORPORATION
			
		 	By:	 	 /s/ Angus Grant

			
		 	Name:	 	 Angus Grant

			
		 	Title:	 	 Vice President


  

			
	Address:	 	86 Morris Avenue
		 	Summit, NJ 07901

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTOR:
		
		 	EcoR1 CAPITAL FUND, L.P.
			
		 	By:	 	 /s/ Oleg Nodelman

			
		 	Name:	 	 Oleg Nodelman

			
		 	Title:	 	 Managing Member, EcoR1 Capital, LLC


  

			
	Address:	 	409 Illinois Street
		 	San Francisco, CA 94158

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTOR:
		
		 	AMGEN INC.
			
		 	By:	 	 /s/ David A. Piacquad

			
		 	Name:	 	 David A. Piacquad

			
		 	Title:	 	 VP Strategy & Corp. Development

			
		 	Address:	 	One Amgen Center Drive
		 		 	Thousand Oaks, CA 91320

  

					
		 	AMGEN INVESTMENTS LTD.
			
		 	By:	 	 /s/ Janis C. Naeve

			
		 	Name:	 	 Janis C. Naeve

			
		 	Title:	 	 Managing Director

			
		 	Address:	 	Canon’s Court
		 		 	22 Victoria Street
		 		 	Hamilton, HM 12
		 		 	Bermuda

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. 

 

					
		 	INVESTOR:
		
		 	ALEXANDRIA EQUITIES, LLC
			
		 	By:	 	 ALEXANDRIA REAL ESTATE
 EQUITIES, INC., managing
member

			
		 	By:	 	 /s/ Jennifer Banks

			
		 	Name:	 	 Jennifer Banks

			
		 	Title:	 	 EVP, General Counsel


  

			
		
	Address:	 	385 East Colorado Boulevard, Suite 299
		 	Pasadena, CA 91101

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTORS:
		
		 	DAG Ventures V-QP, L.P.
			
		 	By:	 	 /s/ Tom Goodrich

		 	Name:	 	Tom Goodrich
		 	Title:	 	Managing Director

  

			
		
	Address:	 	251 Lytton Avenue, Suite 200
		 	Palo Alto, CA 94301

  

					
		 	DAG Ventures V, L.P.
			
		 	By:	 	 /s/ Tom Goodrich

		 	Name:	 	Tom Goodrich
		 	Title:	 	Managing Director

  

			
		
	Address:	 	251 Lytton Avenue, Suite 200
		 	Palo Alto, CA 94301

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTOR:
		
		 	FRANKLIN BERGER, an individual
			
		 	By:	 	 /s/ Franklin Berger


  

			
		
	Address:	 	[*]
		 	

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

							
		 	INVESTORS:
		
		 	DOMAIN PARTNERS VIII, L.P.
			
		 	By:	 	 One Palmer Square Associates VIII, L.L.C.,

its General Partner

				
		 		 	By:	 	 /s/ Lisa Kraeutler

		 		 		 	Lisa Kraeutler
		 		 		 	Attorney-in-Fact

  

			
	Address:	 	One Palmer Square
		 	Suite 515
		 	Princeton, NJ 08542

  

							
		 	DP VIII ASSOCIATES, L.P.
			
		 	By:	 	 One Palmer Square Associates VIII, L.L.C.,

its General Partner

				
		 		 	By:	 	 /s/ Lisa Kraeutler

		 		 		 	Lisa Kraeutler
		 		 		 	Attorney-in-Fact

  

			
	Address:	 	One Palmer Square
		 	Suite 515
		 	Princeton, NJ 08542

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTOR:
		
		 	CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V.
			
		 	By:	 	 /s/ Raul Humberto Zepeda Ruiz

			
		 	Name:	 	 Raul Humberto Zepeda Ruiz

			
		 	Title:	 	 Attorney-in-Fact


  

			
	Address:	 	c/o Inmobiliaria Carso
		 	Paseo de las Palmas 750
		 	6th Floor
		 	Lomas de Chapultepec
		 	Mexico, D.F., 11000

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	INVESTOR:
		
		 	GALLAGHER REVOCABLE TRUST
			
		 	By:	 	 /s/ Carol G. Gallagher

		 		 	Carol G. Gallagher, Trustee

  

			
		
	Address:	 	[*]
		 	

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	COMMON HOLDER/ INVESTOR:
		
		 	KPCB HOLDINGS, INC., as nominee
			
		 	By:	 	 /s/ Paul Vronsky

		 		 	Paul Vronsky, General Counsel

  

			
		
	Address:	 	2750 Sand Hill Road
		 	Menlo Park, CA 94025

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	COMMON HOLDER/ INVESTOR:
		
		 	 ISAAC E. CIECHANOVER AND

ALLISON M. CIECHANOVER FAMILY TRUST
 DATED
8/8/08

			
		 	By:	 	 /s/ Isaac Ciechanover

		 		 	Isaac Ciechanover, Trustee

  

			
		
	Address:	 	[*]
		 	

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

					
		 	COMMON HOLDER:
		
		 	Christopher M. Haqq, MD, PhD, an individual
			
		 	By:	 	 /s/ Christopher M. Haqq


  

			
		
	Address:	 	c/o Atara Biotherapeutics, Inc.
		 	2945 Townsgate Road, Suite 200
		 	Westlake Village, CA 91361

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

									
		 	INVESTORS:
		
		 	BAUPOST PRIVATE INVESTMENTS A-1, L.L.C.
			
		 	By:	 	Baupost Limited Partnership 1983 A-1, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS B-1, L.L.C.
			
		 	By:	 	Baupost Limited Partnership 1983 B-1, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS C-1, L.L.C.
			
		 	By:	 	Baupost Limited Partnership 1983 C-1, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

			
	Address:	 	10 St. James Avenue, 17th Floor
		 	Boston, Massachusetts 02116

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

									
		 	INVESTORS:
		
		 	BAUPOST PRIVATE INVESTMENTS H-1, L.L.C.
			
		 	By:	 	HB Institutional Limited Partnership, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS P-1, L.L.C.
			
		 	By:	 	PB Institutional Limited Partnership, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS Y-1, L.L.C.
			
		 	By:	 	YB Institutional Limited Partnership, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

			
	Address:	 	10 St. James Avenue, 17th Floor
		 	Boston, Massachusetts 02116

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. 
  

									
		 	INVESTORS:
		
		 	BAUPOST PRIVATE INVESTMENTS BVI-1, L.L.C.
			
		 	By:	 	Baupost Value Partners, L.P.-I, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS BVII-1, L.L.C.
			
		 	By:	 	Baupost Value Partners, L.P.-II, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS BVIII-1, L.L.C.
			
		 	By:	 	Baupost Value Partners, L.P.-III, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

									
		 	BAUPOST PRIVATE INVESTMENTS BVIV-1, L.L.C.
			
		 	By:	 	Baupost Value Partners, L.P.-IV, its sole member
				
		 		 	By:	 	The Baupost Group, L.L.C., its managing general partner
					
		 		 		 	By:	 	 /s/ James F. Mooney III

		 		 		 		 	Name: James F. Mooney III
		 		 		 		 	Title: Partner

  

			
	Address:	 	10 St. James Avenue, 17th Floor
		 	Boston, Massachusetts 02116

 Signature Page to Investors’ Rights Agreement for 

Atara Biotherapeutics, Inc. 







 Schedule A 

SCHEDULE OF INVESTORS 
 Isaac E
Ciechanover and Allison M 
 Ciechanover family trust dated 8/8/08 

[*] 
 KPCB Holdings, Inc. as nominee 

2750 Sand Hill Road 
 Menlo Park, CA 94025 

legaldocs@kpcb.com 
 Domain Partners VIII, L.P. 

DP VIII Associates, L.P. 
 One Palmer Square 

Suite 515 
 Princeton, NJ 08542 

DAG Ventures V-QP, L.P. 
 DAG Ventures V, L.P. 

251 Lytton Avenue, Suite 200 
 Palo Alto, CA 94301 

Alexandria Equities, LLC 
 385 East Colorado Blvd.,
Suite 299 
 Pasadena, CA 91101 
 Franklin Berger 

[*] 
 Amgen Inc. 

One Amgen Center Drive 
 Mail Stop 28-5-C 

Thousand Oaks, CA 91320 
 jnaeve@amgen.com 

Control Empresarial de Capitales, S.A. de C.V. 
 c/o Inmobiliaria
Carso 
 Paseo de las Palmas 750 
 6th Floor 
 Lomas de Chapultepec 

Mexico, D.F., 11000 
 Gallagher Revocable Trust 

Carol G. Gallagher, Trustee 
 [*] 

  
 Schedule A 








 Celgene Corporation 

86 Morris Avenue 
 Summit, NJ 07901 

Amgen Investments Ltd. 
 Canon’s Court 22 Victoria Street

 Hamilton, HM 12 Bermuda 
 EcoR1 Capital Fund, L.P. 

409 Illinois Street 
 San Francisco, CA 94158 

BAUPOST PRIVATE INVESTMENTS A-1, L.L.C. 
 BAUPOST PRIVATE
INVESTMENTS B-1, L.L.C. 
 BAUPOST PRIVATE INVESTMENTS C-1, L.L.C. 

BAUPOST PRIVATE INVESTMENTS H-1, L.L.C. 
 BAUPOST PRIVATE
INVESTMENTS P-1, L.L.C. 
 BAUPOST PRIVATE INVESTMENTS Y-1, L.L.C. 

BAUPOST PRIVATE INVESTMENTS BVI-1, L.L.C. 
 BAUPOST PRIVATE
INVESTMENTS BVII-1, L.L.C. 
 BAUPOST PRIVATE INVESTMENTS BVIII-1, L.L.C. 

BAUPOST PRIVATE INVESTMENTS BVIV-1, L.L.C. 
 (shares held by
Boomsail & Co, as nominee) 
 10 St. James Avenue, 17th Floor 

Boston, Massachusetts 02116 

  
 Schedule A 








 Schedule B 

SCHEDULE OF COMMON HOLDERS 
 Isaac E
Ciechanover and Allison M 
 Ciechanover family trust dated 8/8/08 

[*] 
 KPCB Holdings, Inc. as nominee 

2750 Sand Hill Road 
 Menlo Park, CA 94025 

legaldocs@kpcb.com 
 Christopher M. Haqq 

c/o Atara Biotherapeutics, Inc. 
 2945 Townsgate Road,
Suite 200, 
 Westlake Village, CA 91361 

chaqq@atarabio.com 

  
 Schedule B